Frankfurt am Main, Germany: 23rd - 25th October 2015. The "18th Patient and Relatives Meeting" for patients with pulmonary hypertension (PAH) attracted many partipants who listened to the lecture of our colleague Prof. Horst Olschewski, Head of the Division of Pulmonology at the Hospital Graz, Austria about "Future Therapy of PAH". Prof. Olschewski explained the importance of an initial combination therapy, thus, immediately after the diagnosis the treatment is started using two or even more agents. Further studies will focus on the relationship between drug effects and side effects and investigate how humans with different gene variants and disease symptoms respond to the new drug combinations.
In a workshop, Prof. Andrea Olschewski discussed about the „Reasons of lung vessel remodelling“, in another our colleague Dr. Julia Hoffmann talked about the topic „ Pulmonary hypertension: A phenomenon underlying different molecularbiological mechanisms“. Dr. Hoffmann, deeply impressed by the active discussion of the participating patients: „It is a challenging but important task to explain our research directly to the patients.“
More information about this hot topic you can find here (in German): https://www.phev.de/
copyright: Thomas Füßler